CLINICAL TRIALS PROFILE FOR ACYCLOVIR SODIUM
✉ Email this page to a colleague
All Clinical Trials for acyclovir sodium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00045292 ↗ | Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation | Completed | National Cancer Institute (NCI) | Phase 3 | 2002-04-01 | RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of valacyclovir in preventing cytomegalovirus in patients who are undergoing donor stem cell transplantation. |
| NCT00045292 ↗ | Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation | Completed | Fred Hutchinson Cancer Research Center | Phase 3 | 2002-04-01 | RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of valacyclovir in preventing cytomegalovirus in patients who are undergoing donor stem cell transplantation. |
| NCT00774280 ↗ | Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen | Completed | Cooperative Study Group A for Hematology | Phase 3 | 2002-05-01 | 1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8. |
| NCT00855309 ↗ | Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia | Completed | National Cancer Institute (NCI) | Phase 3 | 2008-11-01 | RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for acyclovir sodium
Condition Name
Clinical Trial Locations for acyclovir sodium
Trials by Country
Clinical Trial Progress for acyclovir sodium
Clinical Trial Phase
Clinical Trial Sponsors for acyclovir sodium
Sponsor Name
